Shares of Fusion Pharmaceuticals Rise 7.8% With Study Protocol Aligment Reached
By Ben Glickman Shares of Fusion Pharmaceuticals rose in post-market trading on Thursday after the company had a study protocol approved by regulators. The stock was up 7.8% to $9.10,... -January 04, 2024 at 06:39 pm EST - MarketScreener
John Valliant Ben Glickman Fusion Pharmaceuticals Drug Administration Executive John Valliant Dow Jones
Source: marketscreener.com